Ney Carter Borges։ Clinical Importance of Coronary Microcirculation in MINOCA and INOCA
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
”Clinical Importance of Coronary Microcirculation in MINOCA and INOCA
Coronary microvascular dysfunction (CMD) plays a central and increasingly recognized role in the pathophysiology of angina with non-obstructive coronary arteries, including both myocardial infarction with non-obstructive coronary arteries (MINOCA) and ischemia with non-obstructive coronary arteries (INOCA). Although epicardial coronary arteries may appear angiographically normal or minimally diseased, impairment of the coronary microcirculation leads to inadequate myocardial perfusion, ischemia, and adverse clinical outcomes.
Epidemiological data indicate that INOCA affects up to 40–50% of patients undergoing coronary angiography for angina, with a higher prevalence in women, particularly post-menopausal. In MINOCA, which accounts for approximately 5–10% of all myocardial infarctions, coronary microvascular dysfunction, microvascular spasm, and microembolization are implicated in up to 50–60% of cases when systematically investigated with invasive or advanced imaging techniques.
From a prognostic perspective, CMD is far from benign. Patients with INOCA and documented microvascular dysfunction have a 2–4-fold increased risk of major adverse cardiovascular events (MACE), including cardiovascular death, heart failure hospitalization, and recurrent angina. Reduced coronary flow reserve (CFR <2.0) has been independently associated with a 3-fold increase in cardiovascular mortality over long-term follow-up. Similarly, MINOCA patients demonstrate annual MACE rates of 3–5%, comparable to those observed in patients with obstructive coronary artery disease.
Recognition of coronary microcirculatory pathology in MINOCA and INOCA is therefore critical, not only for accurate diagnosis but also for risk stratification and targeted therapy, shifting clinical focus beyond the epicardial arteries toward the microvascular substrate of ischemic heart disease.
1. Taqueti VR, Di Carli MF.
Coronary microvascular disease: mechanisms and clinical implications.
J Am Coll Cardiol. 2018.
2. Ong P, Camici PG, et al.
Coronary microvascular dysfunction and microvascular angina.
Eur Heart J. 2018.
3. Tamis-Holland JE, et al.
MINOCA: contemporary diagnosis and management.
Circulation. 2019.
4. Pasupathy S, et al.
Myocardial infarction with nonobstructive coronary arteries.
Circulation. 2015.
5. Knuuti J, et al.
ESC Guidelines on chronic coronary syndromes.
Eur Heart J. 2020.”

Stay updated with Hemostasis Today.
-
Aug 31, 2026, 14:32Mahir Khalil Ibrahim Jallo: Hot Topic From The ESC 2026 Munich
-
Aug 31, 2026, 14:28Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
-
Aug 31, 2026, 14:28Francisco Chacón-Lozsán: Should We Anticoagulate AF Patients With Only One Non-Sex Stroke Risk Factor?
-
Aug 31, 2026, 14:24Akl Fahed: Do Lifelong Differences in LDL Cholesterol Influence the Risk of Venous Thromboembolism?
-
Aug 31, 2026, 14:23Accelerating CAR-T Access Through Policy and System Reform – American Society of Hematology
-
Aug 31, 2026, 14:21Shirya Rashid: Does Bempedoic Acid Influence Venous Thromboembolism Risk?
-
Aug 31, 2026, 14:14Jason Andrade: SINGLE-AF Trial Validates Early Anticoagulation in AF
-
Aug 31, 2026, 14:12Leonardo Roever: Diagnosis and Management of Natural Anticoagulant Deficiencies
-
Aug 31, 2026, 14:07Ben Dowsing: Can Heart Failure Therapy Be Safely Withdrawn After HER2 Cardiotoxicity Recovery